Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
Authors
Keywords
-
Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-11-24
DOI
10.1093/ndt/gfab335
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
- (2021) David Z. I. Cherney et al. DIABETOLOGIA
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Mechanisms Leading to Differential Hypoxia Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics
- (2020) Milton Packer AMERICAN JOURNAL OF KIDNEY DISEASES
- Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis
- (2020) Jonathan P. Troost et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
- (2020) David C Wheeler et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
- (2020) John J.V. McMurray et al. CIRCULATION
- Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- (2019) Brad H. Rovin et al. KIDNEY INTERNATIONAL
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
- (2019) Carol Pollock et al. Lancet Diabetes & Endocrinology
- Predicting individual treatment response in diabetes
- (2019) Hiddo J L Heerspink Lancet Diabetes & Endocrinology
- Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
- (2019) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Advanced therapeutics in focal and segmental glomerulosclerosis
- (2018) Yunzi Liu et al. NEPHROLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis
- (2014) Lesley A. Inker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)
- (2013) Hiddo J. Lambers Heerspink et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Clinical trial of focal segmental glomerulosclerosis in children and young adults
- (2011) Debbie S. Gipson et al. KIDNEY INTERNATIONAL
- Focal Segmental Glomerulosclerosis
- (2011) Vivette D. D'Agati et al. NEW ENGLAND JOURNAL OF MEDICINE
- The incidence of primary glomerulonephritis worldwide: a systematic review of the literature
- (2010) A. McGrogan et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started